Summary & Overview
CPT 0492U: CellSearch PD–L1 Circulating Tumor Cell Test
CPT code 0492U designates the CellSearch® PD–L1 Circulating Tumor Cell (CTC–PD–L1) Test, a Proprietary Laboratory Analyses (PLA) code that describes a manufacturer-specific blood-based assay to select circulating tumor cells and quantify PD–L1 expression. The code matters nationally as an emerging companion diagnostic approach for assessing tumor PD–L1 status via liquid biopsy, with implications for immunotherapy selection, disease monitoring, and precision oncology workflows. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn the clinical purpose and laboratory setting for the test, payer coverage considerations, and operational details relevant to billing and specimen handling. The publication summarizes what the code represents, where the service is typically performed, and which major national payers are relevant to coverage discussions. It also outlines common modifiers and where to locate additional documentation for a proprietary assay. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Billing Code Overview
CPT code 0492U is a Proprietary Laboratory Analyses (PLA) code that applies only to the CellSearch® PD–L1 Circulating Tumor Cell (CTC–PD–L1) Test from Menarini Silicon Biosystems Inc. The test uses circulating tumor cell (CTC) selection and biomarker analysis to identify and quantify PD–L1 expression on tumor cells in blood, providing a liquid-biopsy assessment of tumor PD–L1 status.
Service Type: Proprietary laboratory molecular/biomarker analysis of circulating tumor cells
Typical Site of Service: Clinical laboratory or specialized diagnostic laboratory; sample collection typically occurs in an outpatient phlebotomy or clinical setting
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a history of metastatic non-small cell lung cancer (NSCLC) undergoing systemic therapy presents for biomarker monitoring. The oncology team orders a CellSearch® PD–L1 Circulating Tumor Cell (CTC–PD–L1) Test to quantify PD‑L1 expression on circulating tumor cells from a peripheral blood draw to help characterize tumor biology and potentially inform treatment selection or clinical trial eligibility. Blood is collected in appropriate anticoagulant tubes and sent to the Menarini Silicon Biosystems Inc. laboratory or an authorized facility. The lab performs CTC selection and immunophenotypic analysis, reports the number of CTCs and PD‑L1 expression metrics. Results are returned to the ordering oncologist, who incorporates the findings into the overall clinical assessment and treatment planning. Typical site of service is an outpatient phlebotomy clinic, oncology infusion center, or hospital outpatient department where blood collection and specimen transport are available.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no special circumstance applies |
26 | Professional component | When only the professional component (interpretation) is billed separately |
52 | Reduced services | When the laboratory performs a limited version of the test |
53 | Discontinued procedure | If specimen collection or processing is started but stopped for extraordinary circumstances |
62 | Two surgeons | Rarely used; applicable if two independent providers share responsibility for the specimen collection process |
78 | Unplanned return to the operating/procedure room by same physician following initial procedure | If an unexpected procedural complication requires re-collection in the same operative setting |
80 | Assistant surgeon | If an assistant surgeon participates in a collection procedure requiring surgical assistance |
82 | Assistant surgeon when a qualified resident is not available | As above when resident coverage is absent |
TC | Technical component | When billing only the technical component (laboratory processing and analysis) |
QK | Medical direction of two, three, or four CRNAs by a physician | If a CRNA-directed procedure is involved in specimen collection under physician direction |
QX | CRNA service: when CRNA performs service without medical direction | As above when the CRNA operates independently |
QY | Medical direction of one CRNA by a physician | As above when a single CRNA is directed by a physician |
SH | Diagnostic radiology services performed under supervision of a physician | If image‑guided vascular access is used for blood collection under direct supervision |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207Q00000X | Medical Oncology | Primary ordering specialty for CTC PD‑L1 testing |
| 207L00000X | Hematology | May order or interpret circulating cell analyses |
| 208D00000X | Diagnostic Radiology | May assist with image‑guided vascular access for complex blood draws |
| 261QM0800X | Clinical Laboratory | Laboratory directors and pathologists overseeing processing and reporting |
| 207K00000X | Surgical Oncology | May order testing for surgical oncology patients for systemic therapy planning |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung | NSCLC is a common indication for PD‑L1 testing on tissue or CTCs to inform therapy selection |
C50.912 | Malignant neoplasm of unspecified site of right female breast | Breast cancer with metastatic disease can be evaluated with CTC assays for biomarker expression |
C71.9 | Malignant neoplasm of brain, unspecified | Metastatic or primary CNS tumors may prompt circulating biomarker testing in select contexts |
C79.51 | Secondary malignant neoplasm of bone | Metastatic disease monitoring via CTCs can aid in systemic disease characterization |
C78.7 | Secondary malignant neoplasm of liver | Liver metastases are common in multiple solid tumors where CTC biomarker assessment may be utilized |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
36415 | Collection of venous blood by venipuncture | Typical specimen collection method performed before sending sample for the CTC PD‑L1 test |
81025 | Urine pregnancy test, performed in laboratory, qualitative | Often ordered for reproductive‑aged patients before initiating certain systemic therapies; may be part of pre‑treatment lab panel |
88384 | Immunohistochemistry (IHC) with further interpretation and report, per single antigen/antibody stain | Related technique for tissue PD‑L1 assessment; complements blood‑based PD‑L1 testing in workflow |
86328 | Protein; C‑reactive protein (CRP), high sensitivity | Example ancillary laboratory marker; not specific but commonly ordered in oncology monitoring panels |
0000U | Proprietary laboratory analysis (example PLA) | Other PLA codes may be billed for proprietary molecular or cellular assays in the same workflow (use specific code for the test performed) |